Development of NIVA HF, which is being prepared for submission for De Novo regulatory clearance, is supported by a Fast-Track grant provided by the National Institutes of Health (NIH) and LaunchTN SBIR/STTR Matching Fund Program. VoluMetrix notes the NIVA HF is an investigational device designed to monitor the venous waveform, a novel physiologic signal, in heart failure patients, and represents the company’s flagship application for its Non-Invasive Venous waveform Analysis (NIVA) technology. VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital monitoring to enhance well-being, today announced that its NIVA HF device has been designated as a Breakthrough Device by the U.S.
0 kommentar(er)
